Optical probe for in situ assessment of pulmonary fibrosis

用于肺纤维化原位评估的光学探头

基本信息

批准号：
9907714
负责人：
NICUSOR IFTIMIA
金额：
$ 23万
依托单位：
PHYSICAL SCIENCES, INC
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9907714
关键词：
Air Sacs Animal Model Animals Biopsy Birefringence Bleomycin Blood Blood Circulation Breathing Bronchioles Caliber Chest wall structure Chronic Cicatrix Clinical Collaborations Complex Connective Tissue Critical Care Data Development Diagnosis Diagnostic Disease Emotional Evaluation Excision Exposure to Fibrosis General Anesthesia General Hospitals Goals Government Health Health Care Costs Healthcare Hemorrhage Histology Human Image Imaging technology In Situ Inflammation Israel Laboratories Lateral Letters Lung Lung diseases Massachusetts Measures Medicine Microanatomy Microscopy Modeling Morbidity - disease rate Morphology Needles Office Visits Optical Biopsy Optical Coherence Tomography Optics Oxygen Pathologic Pathology Patients Pattern Persons Phase Pilot Projects Procedures Process Pulmonary Fibrosis Quality of life Radiologic Finding Radiology Specialty Rattus Research Resolution Resources Roentgen Rays Safety Scientist Sensitivity and Specificity Services Shortness of Breath Sterilization Stethoscopes Structure Technology Testing Tissues Tube United States X-Ray Computed Tomography accurate diagnosis base clinical research site cost experience experimental study human model idiopathic pulmonary fibrosis imaging probe improved in vivo in vivo evaluation instrument lung imaging mechanical properties minimally invasive multidisciplinary new technology novel optical imaging physical science pre-clinical procedure cost programs rapid diagnosis side effect success technology development tissue processing

Air Sacs Animal Model Animals Biopsy Birefringence Bleomycin Blood Blood Circulation Breathing Bronchioles Caliber Chest wall structure Chronic Cicatrix Clinical Collaborations Complex Connective Tissue Critical Care Data Development Diagnosis Diagnostic Disease Emotional Evaluation Excision Exposure to Fibrosis General Anesthesia General Hospitals Goals Government Health Health Care Costs Healthcare Hemorrhage Histology Human Image Imaging technology In Situ Inflammation Israel Laboratories Lateral Letters Lung Lung diseases Massachusetts Measures Medicine Microanatomy Microscopy Modeling Morbidity - disease rate Morphology Needles Office Visits Optical Biopsy Optical Coherence Tomography Optics Oxygen Pathologic Pathology Patients Pattern Persons Phase Pilot Projects Procedures Process Pulmonary Fibrosis Quality of life Radiologic Finding Radiology Specialty Rattus Research Resolution Resources Roentgen Rays Safety Scientist Sensitivity and Specificity Services Shortness of Breath Sterilization Stethoscopes Structure Technology Testing Tissues Tube United States X-Ray Computed Tomography accurate diagnosis base clinical research site cost experience experimental study human model idiopathic pulmonary fibrosis imaging probe improved in vivo in vivo evaluation instrument lung imaging mechanical properties minimally invasive multidisciplinary new technology novel optical imaging physical science pre-clinical procedure cost programs rapid diagnosis side effect success technology development tissue processing

展开

项目摘要

Project Summary/Abstract Physical Sciences Inc. (PSI), in collaboration with the Department of Pathology at the Massachusetts General Hospital (MGH) and the Divisions of Pulmonary and Critical Care Medicine at MGH and Beth Israel Lahey Health (BILH), proposes to develop and evaluate a novel technology for assessing pulmonary fibrosis, which is a respiratory disease leading to serious breathing problems. This disease consists of the accumulation of excess fibrous connective tissue within the lungs (this process is called fibrosis), leading to thickening of the walls of the bronchioles, and thus causes reduced oxygen supply in the blood. As a consequence patients suffer from perpetual shortness of breath. Pulmonary fibrosis is usually diagnosed during regular doctor office visits, by listening with the stethoscope, and confirmed with X-rays and CT scanning. However, since misdiagnosis is common, biopsy is ultimately performed to confirm findings. Unfortunately, large pieces of tissue are needed to evaluate the presence of fibrosis. Therefore, video assisted thoracoscopic wedge biopsy (VATS) is used for this purpose. This procedure has multiple side effects, including inflammation, tissue morbidity, and severe bleeding. Furthermore, since it requires tissue processing and pathologic interpretation, the procedure becomes expensive, while the results are not immediately available. PSI's proposed alternative approach to regular VATS wedge resections is to investigate tissue morphology and mechanical properties in situ by using a minimally invasive needle-type smart optical probe, which eliminates the need to remove any tissue. Furthermore, the results are immediately available during biopsy. This technology will be first tested In Phase I in a Bleomycin-induced pulmonary fibrosis rat model to determine its efficacy for reliable diagnosis. Based on Phase I findings, the technology will be further improved during Phase II and its efficacy will be further tested in human patients at MGH and BILH. Successful development and demonstration of the proposed PSI technology will enable reliable improved diagnosis at lower costs while eliminating side effects associated to the regular biopsy.

项目摘要/摘要物理科学公司（PSI），与马萨诸塞州病理学系合作综合医院（MGH）以及MGH和Beth Israel的肺和重症监护医学的划分 Lahey Health（BILH）建议开发和评估一种评估肺纤维化的新技术，这是一种导致严重呼吸问题的呼吸道疾病。这种疾病包括积累肺内过量的纤维结缔组织（此过程称为纤维化），导致细支气管的壁，因此导致血液中的氧气供应减少。结果患者呼吸急促。通常在常规医生办公室期间诊断出肺纤维化通过听诊器聆听，并通过X射线和CT扫描确认。但是，自从误诊是常见的，最终进行活检以确认发现。不幸的是，大块需要组织来评估纤维化的存在。因此，视频协助胸腔镜楔活检（桶）用于此目的。该过程具有多种副作用，包括炎症，组织发病率和严重的出血。此外，由于它需要组织加工和病理解释，因此该过程变得昂贵，而结果尚未立即可用。 PSI提出的替代方法是常规桶楔切除术是研究组织形态通过使用微创针头型智能光学探针，原位机械性能，该探针消除了去除任何组织的需求。此外，在活检期间，结果可立即获得。该技术将首先在第一阶段进行测试博来霉素诱导的肺纤维化大鼠模型确定它的可靠诊断功效。根据第一阶段的发现，该技术将在第二阶段及其功效将在MGH和BILH的人类患者中进一步测试。成功发展拟议的PSI技术的演示将以较低的成本来改善可靠的诊断消除与定期活检有关的副作用。